Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Septic Shock

Septic Shock

Part of Systemic Inflammatory Response Syndrome

Subtypes of Septic Shock

Endotoxic septic shock 1

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Septic Shock

39 trials tracked for Septic Shock: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 365 citations.

39Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 3 Phase 3 5 Phase 2 17 Phase 1 2 Other / NA 12
  1. Phase 3 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis Completed · 365 cited
  2. Phase 3 Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial Completed · 252 cited
  3. Phase 4 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial Completed · 110 cited
  4. Phase 3 Statin Therapy in the Treatment of Sepsis Completed · 62 cited
  5. Phase 3 Vitamin C and Septic Shock Completed · 62 cited
  6. Phase 4 Renin and Renal Biomarker Response to Angiotensin II Completed
Show 33 more trials
  1. Phase 4 Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock Completed
  2. Phase 3 Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock Completed
  3. Phase 2 Ascorbic Acid (Vitamin C) Infusion in Human Sepsis Completed
  4. Phase 2 A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock Completed
  5. Phase 2 Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia Completed
  6. Phase 2 Rapid Administration of Carnitine in sEpsis Completed
  7. Phase 2 LIPIDS-P Trial Phase I/II Trial Completed
  8. Phase 2 Thiamine as a Metabolic Resuscitator in Septic Shock Completed
  9. Phase 2 A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock Completed
  10. Phase 2 HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients Completed
  11. Phase 2 Acetyl-L-Carnitine in the Treatment of Septic Shock Completed
  12. Phase 2 Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock Completed
  13. Phase 2 Effects of the V1a Agonist FE 202158 in Patients With Septic Shock Completed
  14. Phase 2 Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis. Completed
  15. Phase 2 Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB Completed
  16. Phase 2 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock Completed
  17. Phase 2 A Trial of Vitamin B12 in Septic Shock Completed
  18. Phase 2 Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock Completed
  19. Phase 2 Vitamin C & Thiamine to Treat Sepsis and Septic Shock Completed
  20. Phase 1 Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study Completed
  21. Phase 1 Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study Completed
  22. N/A Protocolized Care for Early Septic Shock Completed
  23. N/A Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM) Completed
  24. N/A Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock Completed
  25. N/A The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation Completed
  26. N/A Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock Completed
  27. N/A Early Warning System for Clinical Deterioration on General Hospital Wards Completed
  28. N/A Release of Nociceptin From Granulocytes in Sepsis Completed
  29. N/A Initiation of Hydrocortisone for the Treatment of Septic Shock Completed
  30. N/A Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock Completed
  31. N/A Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department Completed
  32. N/A High MAP in Septic Shock With Hypertension Completed
  33. N/A PK Analysis of Piperacillin in Septic Shock Patients Completed

Showing the 39 most-cited and recently-updated of 39 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Septic Shock: what the trials found

Evidence regarding the timing and type of hemodynamic support shows that early vasopressors did not significantly impact mortality by day 90 (p=0.61) or change the number of organ support-free days or ventilator-free days 5. Angiotensin II was associated with a median of 0.9 days to discontinuation of catecholamines compared to 3.5 days in the control group, and significantly more renal replacement therapy-free days (21 vs 0) 3.

The use of Vitamin C has shown mixed results across trials; one study reported a significant reduction in time to vasopressor independence (p<0.001) 13, while other studies showed no statistically significant differences in mortality rates 12 or SOFA scores 8. A combination of vitamin C, vitamin B1, and hydrocortisone did not significantly improve SOFA scores at 72 hours (p=0.12) or reduce the rate of renal failure (p=0.58), though a trend toward lower 30-day mortality was observed (p=0.05) 6.

Other interventions included isotonic crystalloids, which showed no significant difference in days alive and out of hospital at day 90 compared to the control group 2. Drotrecogin alfa did not show statistically significant improvements in cumulative vasopressor index (p=0.238), change in CVI over 96 hours (p=0.478), or mean arterial pressure (p=0.442) 4.

Additional established trials included the use of simvastatin 7, dopamine 9, and ascorbic acid 22.

Recent results — preliminary, needs further review

  • Hydroxocobalamin was evaluated in a Phase 2 trial 1.
  • Smoflipid was assessed for its effect on total cholesterol levels over 48 hours 10.

For the clinician treating this condition

  • Early vasopressor initiation does not appear to significantly alter mortality or duration of organ support in the studied cohort.
  • Ascorbic acid (Vitamin C) shows conflicting evidence regarding its impact on clinical outcomes, with significant results for vasopressor independence but non-significant results for mortality and SOFA scores in other trials.
  • Angiotensin II was associated with faster discontinuation of catecholamines and increased renal replacement therapy-free days.

AI synthesis of 13 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Neostigmine infusion in septic shock linked to lower TNF-alpha and 28-day mortality in single-center RCT
Emergency Medicine RCT
Neostigmine infusion in septic shock linked to lower TNF-alpha and 28-day mortality in single-center RCT Neostigmine infusion linked to lower inflammation and mortality in septic shock trial
A single-center randomized controlled trial in adult ICU patients with septic shock compared a 5-day neostigmine infusion (0.2 mg/hr) to pla…
Septic shock patients receiving neostigmine showed lower inflammation, better organ scores, and fewer deaths compared to those on placebo in…
Apr 7, 2026
Corticosteroids in cirrhotic shock show no mortality benefit but increase bleeding and organ failure risk
Gastroenterology Meta-analysis
Corticosteroids in cirrhotic shock show no mortality benefit but increase bleeding and organ failure risk Corticosteroids help resolve shock in cirrhosis patients but don't improve survival
A meta-analysis of 514 cirrhotic patients with septic or distributive shock found low-dose corticosteroids did not reduce in-hospital mortal…
Low-dose corticosteroids help resolve shock in cirrhosis patients but do not improve overall survival and increase bleeding risks.
Apr 6, 2026
Network meta-analysis finds PMX and HA 330 blood purification may reduce mortality in severe septic shock
Emergency Medicine
Network meta-analysis finds PMX and HA 330 blood purification may reduce mortality in severe septic shock Two blood purification devices linked to lower death rates in severe septic shock
A Bayesian network meta-analysis of 31 RCTs involving 2678 patients with severe septic shock found that the TORAYMYXIN™ filter (PMX) and HA …
Two specific blood purification devices are linked to lower death rates for patients with severe septic shock compared to standard treatment…
Apr 2, 2026
Balanced salt solution in pediatric septic shock linked to lower AKI and RRT rates versus normal saline
Emergency Medicine Meta-analysis
Balanced salt solution in pediatric septic shock linked to lower AKI and RRT rates versus normal saline Balanced fluids may reduce kidney injury in children with septic shock, study finds
A meta-analysis of 5 RCTs involving 992 children with septic shock found balanced salt solution (BSS) was not associated with reduced mortal…
Using balanced salt solutions instead of normal saline helps children with septic shock avoid kidney injury and dialysis, a new analysis of …
Apr 2, 2026
VR and in-person sepsis simulation show similar skill outcomes in medical student pilot study
Emergency Medicine RCT
VR and in-person sepsis simulation show similar skill outcomes in medical student pilot study Can virtual reality teach doctors to spot sepsis as well as real training?
A randomized comparative pilot study of 32 final-year medical students found no statistically significant differences in mQSAT scores or sep…
Virtual reality training helped medical students spot when patients needed intensive care better than traditional practice methods in a new …
Apr 2, 2026

Questions about Septic Shock

Do doctors need to give extra oxygen to patients with septic shock?

Yes, doctors often give extra oxygen to septic shock patients, but recent evidence shows conservative oxygen targets (SpO2 88-94%) are as safe as liberal targets, with no difference in mortality.

Full answer →
Is it better to have high or low pulse pressure when you have septic shock?

In septic shock, a pulse pressure between 40-70 mmHg during the first 24 hours is linked to lower 28-day mortality; both very low and very high pulse pressure are associated with worse outcomes.

Full answer →